{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:29:57Z","timestamp":1787506197687,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"am","delay-in-days":312,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R37NS076752"],"award-info":[{"award-number":["R37NS076752"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Genetics & Development"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.gde.2025.102346","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:51:21Z","timestamp":1744152681000},"page":"102346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["No more nonsense: evaluating poison exons as therapeutic targets in neurodevelopmental disorders"],"prefix":"10.1016","volume":"92","author":[{"given":"Shreeya","family":"Bakshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9479-6729","authenticated-orcid":false,"given":"Lori L","family":"Isom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gde.2025.102346_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrg2776","article-title":"Alternative splicing and evolution: diversification, exon definition and function","volume":"11","author":"Keren","year":"2010","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.gde.2025.102346_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng0102-13","article-title":"A genomic view of alternative splicing","volume":"30","author":"Modrek","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.gde.2025.102346_bib3","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/nature05676","article-title":"Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements","volume":"446","author":"Lareau","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.gde.2025.102346_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)80542-5","article-title":"A perfect message: RNA surveillance and nonsense-mediated decay","volume":"96","author":"Hentze","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.gde.2025.102346_bib5","article-title":"Nonsense-mediated mRNA decay in human health and diseases: current understanding, regulatory mechanisms and future perspectives","author":"Behera","year":"2024","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.gde.2025.102346_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.conb.2017.05.012","article-title":"Beyond proteome diversity: alternative splicing as a regulator of neuronal transcript dynamics","volume":"45","author":"Mauger","year":"2017","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.gde.2025.102346_bib7","article-title":"Poison exon annotations improve the yield of clinically relevant variants in genomic diagnostic testing","author":"Felker","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.gde.2025.102346_bib8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1101\/gad.1525507","article-title":"Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay","volume":"21","author":"Ni","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.gde.2025.102346_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000516143","article-title":"Targeting poison exons to treat developmental and epileptic encephalopathy","volume":"43","author":"Aziz","year":"2021","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.gde.2025.102346_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.gde.2020.05.030","article-title":"Poison exons in neurodevelopment and disease","volume":"65","author":"Carvill","year":"2020","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.gde.2025.102346_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-023-03004-w","article-title":"Mapping genetic variants for nonsense-mediated mRNA decay regulation across human tissues","volume":"24","author":"Sun","year":"2023","journal-title":"Genome Biol"},{"key":"10.1016\/j.gde.2025.102346_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1042\/BST20150168","article-title":"Mutation of genes controlling mRNA metabolism and protein synthesis predisposes to neurodevelopmental disorders","volume":"43","author":"Sartor","year":"2015","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.gde.2025.102346_bib13","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1073\/pnas.1502849112","article-title":"Systematic discovery of regulated and conserved alternative exons in the mammalian brain reveals NMD modulating chromatin regulators","volume":"112","author":"Yan","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.gde.2025.102346_sbref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105622","article-title":"Sodium channel expression and transcript variation in the developing brain of human, Rhesus monkey, and mouse","volume":"164","author":"Heighway","year":"2022","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.gde.2025.102346_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.27818","article-title":"Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: treatment experience in clinical practice","volume":"67","author":"Meyer","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.gde.2025.102346_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102271","article-title":"Molecular mechanisms and antisense oligonucleotide therapies of familial amyotrophic lateral sclerosis","volume":"35","author":"Al Dera","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.gde.2025.102346_bib17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.gde.2025.102346_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103691","article-title":"Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm","volume":"74","author":"Grabowska-Pyrzewicz","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.gde.2025.102346_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813743","article-title":"Emerging gene therapy approaches in the management of spinal muscular atrophy (SMA): an overview of clinical trials and patent landscape","volume":"24","author":"Ponomarev","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gde.2025.102346_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17460441.2022.2149733","article-title":"RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides","volume":"18","author":"Torroba","year":"2023","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.gde.2025.102346_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16172940","article-title":"Therapeutic antisense oligonucleotides in oncology: from bench to bedside","volume":"16","author":"Cakan","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.gde.2025.102346_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1474-4422(23)00001-7","article-title":"Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1\/2a trial","volume":"22","author":"Thornton","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.gde.2025.102346_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/npr2.12335","article-title":"Systemic administration of the antisense oligonucleotide NS-089\/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: study protocol for a phase I\/II clinical trial","volume":"43","author":"Ishizuka","year":"2023","journal-title":"Neuropsychopharmacol Rep"},{"key":"10.1016\/j.gde.2025.102346_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030778","article-title":"Recent trends in antisense therapies for duchenne muscular dystrophy","volume":"15","author":"Wilton-Clark","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.gde.2025.102346_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.gde.2025.102346_bib26","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.gde.2025.102346_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17093-9","article-title":"Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression","volume":"11","author":"Lim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.gde.2025.102346_bib28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ymthe.2020.12.022","article-title":"Clinical applications of single-stranded oligonucleotides: current landscape of approved and in-development therapeutics","volume":"29","author":"Scharner","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.gde.2025.102346_bib29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/jmg.2008.062323","article-title":"Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients","volume":"46","author":"Depienne","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.gde.2025.102346_bib30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0b013e31820c309b","article-title":"Genotype-phenotype associations in SCN1A-related epilepsies","volume":"76","author":"Zuberi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.gde.2025.102346_bib31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ajhg.2018.10.023","article-title":"Aberrant inclusion of a poison exon causes dravet syndrome and related SCN1A-associated genetic epilepsies","volume":"103","author":"Carvill","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.gde.2025.102346_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009195","article-title":"Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy","volume":"17","author":"Voskobiynyk","year":"2021","journal-title":"PLoS Genet"},{"key":"10.1016\/j.gde.2025.102346_sbref33","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/brain\/awad349","article-title":"Antisense oligonucleotides restore excitability, GABA signalling and sodium current density in a Dravet syndrome model","volume":"147","author":"Yuan","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.gde.2025.102346_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147743","article-title":"Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome","volume":"1775","author":"Wengert","year":"2022","journal-title":"Brain Res"},{"key":"10.1016\/j.gde.2025.102346_bib35","unstructured":"Sullivan, J. et al. (2024) : Zorevunersen (STK-001) Demonstrates Potential for Disease Modification Including Reductions in Seizures and Improvements in Cognition and Behavior in Children and Adolescents with Dravet Syndrome (DS); AES 2024 Annual Meeting Abstract Database. AESnet.org."},{"key":"10.1016\/j.gde.2025.102346_bib36","unstructured":"Neuray, C. et al. (2024) : Spectral EEG Analysis Demonstrates Decreased Slow-wave Activity in Patients with Dravet Syndrome (DS) After Treatment with STK-001, an Antisense Oligonucleotide (ASO); AES 2024 Annual Meeting Abstract Database 2024. AESnet.org."},{"key":"10.1016\/j.gde.2025.102346_bib37","unstructured":"Perry, M.S. et al. (2024) : Patients With Dravet Syndrome in Open-Label Extension Studies of Zorevunersen (STK-001) Have Durable Reductions in Seizure Frequency and Clinically Meaningful Improvements in Cognition and Behavior; AES 2024 Annual Meeting Abstract Database. AESnet.org."},{"key":"10.1016\/j.gde.2025.102346_bib38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1523\/JNEUROSCI.23-04-01119.2003","article-title":"The role of synaptic GTPase-activating protein in neuronal development and synaptic plasticity","volume":"23","author":"Kim","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.gde.2025.102346_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa0805392","article-title":"Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation","volume":"360","author":"Hamdan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gde.2025.102346_bib40","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/WNL.0000000000006729","article-title":"SYNGAP1 encephalopathy: a distinctive generalized developmental and epileptic encephalopathy","volume":"92","author":"Vlaskamp","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.gde.2025.102346_bib41","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.cell.2019.12.036","article-title":"Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism","volume":"180","author":"Satterstrom","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.gde.2025.102346_sbref39","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.neuron.2023.02.021","article-title":"Upregulation of SYNGAP1 expression in mice and human neurons by redirecting alternative splicing","volume":"111","author":"Yang","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.gde.2025.102346_bib43","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature14142","article-title":"RBM3 mediates structural plasticity and protective effects of cooling in neurodegeneration","volume":"518","author":"Peretti","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.gde.2025.102346_bib44","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000884","article-title":"TrkB signaling regulates the cold-shock protein RBM3-mediated neuroprotection","volume":"4","author":"Peretti","year":"2021","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.gde.2025.102346_sbref42","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217157","article-title":"ASO targeting RBM3 temperature-controlled poison exon splicing prevents neurodegeneration in vivo","volume":"15","author":"Preussner","year":"2023","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.gde.2025.102346_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102101","article-title":"Regulating PCCA gene expression by modulation of pseudoexon splicing patterns to rescue enzyme activity in propionic acidemia","volume":"35","author":"Spangsberg Petersen","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.gde.2025.102346_bib47","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188014","article-title":"Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome","author":"Tang","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.gde.2025.102346_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102801","article-title":"Identifying potent nonsense-mediated mRNA decay inhibitors with a novel screening system","volume":"11","author":"Carrard","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.gde.2025.102346_bib49","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/gtc.12033","article-title":"Role of SMG-1-mediated Upf1 phosphorylation in mammalian nonsense-mediated mRNA decay","volume":"18","author":"Yamashita","year":"2013","journal-title":"Genes Cells"},{"key":"10.1016\/j.gde.2025.102346_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11030722","article-title":"Nonsense-mediated mRNA decay factor functions in human health and disease","volume":"11","author":"Sun","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.gde.2025.102346_bib51","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.bmcl.2012.08.107","article-title":"Identification of pyrimidine derivatives as hSMG-1 inhibitors","volume":"22","author":"Gopalsamy","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.gde.2025.102346_bib52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1261\/rna.080066.124","article-title":"NMDtxDB: data-driven identification and annotation of human NMD target transcripts","volume":"30","author":"Britto-Borges","year":"2024","journal-title":"RNA"},{"key":"10.1016\/j.gde.2025.102346_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27423-0","article-title":"Cellular variability of nonsense-mediated mRNA decay","volume":"12","author":"Sato","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.gde.2025.102346_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2156-9-83","article-title":"Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues","volume":"9","author":"Zetoune","year":"2008","journal-title":"BMC Genet"},{"key":"10.1016\/j.gde.2025.102346_bib55","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cell.2013.04.056","article-title":"Regulation of axon guidance by compartmentalized nonsense-mediated mRNA decay","volume":"153","author":"Colak","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.gde.2025.102346_bib56","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.neuron.2022.12.015","article-title":"mRNA transport, translation, and decay in adult mammalian central nervous system axons","volume":"111","author":"Jung","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.gde.2025.102346_sbref54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41556-020-00618-1","article-title":"Loss of the fragile X syndrome protein FMRP results in misregulation of nonsense-mediated mRNA decay","volume":"23","author":"Kurosaki","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.gde.2025.102346_bib58","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1016\/j.molcel.2022.10.018","article-title":"Integrative omics indicate FMRP sequesters mRNA from translation and deadenylation in human neuronal cells","volume":"82","author":"Kurosaki","year":"2022","journal-title":"Mol Cell"},{"key":"10.1016\/j.gde.2025.102346_bib59","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-023-03146-x","article-title":"FMRP-mediated spatial regulation of physiologic NMD targets in neuronal cells","volume":"25","author":"Kurosaki","year":"2024","journal-title":"Genome Biol"}],"container-title":["Current Opinion in Genetics & Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959437X25000383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959437X25000383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:22:59Z","timestamp":1778300579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959437X25000383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":59,"alternative-id":["S0959437X25000383"],"URL":"https:\/\/doi.org\/10.1016\/j.gde.2025.102346","relation":{},"ISSN":["0959-437X"],"issn-type":[{"value":"0959-437X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No more nonsense: evaluating poison exons as therapeutic targets in neurodevelopmental disorders","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Genetics & Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gde.2025.102346","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102346"}}